These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15958589)

  • 1. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
    MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
    Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
    Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
    Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
    Gao N; Kramer L; Rahmani M; Dent P; Grant S
    Mol Pharmacol; 2006 Aug; 70(2):645-55. PubMed ID: 16672643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
    Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
    Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
    Gojo I; Zhang B; Fenton RG
    Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.
    Hallaert DY; Spijker R; Jak M; Derks IA; Alves NL; Wensveen FM; de Boer JP; de Jong D; Green SR; van Oers MH; Eldering E
    Cell Death Differ; 2007 Nov; 14(11):1958-67. PubMed ID: 17703234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
    Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
    Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.
    Garrofé-Ochoa X; Cosialls AM; Ribas J; Gil J; Boix J
    Apoptosis; 2011 Jul; 16(7):660-70. PubMed ID: 21505869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis.
    Leitch AE; Riley NA; Sheldrake TA; Festa M; Fox S; Duffin R; Haslett C; Rossi AG
    Eur J Immunol; 2010 Apr; 40(4):1127-38. PubMed ID: 20127676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
    Gomez-Bougie P; Bataille R; Amiot M
    Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
    Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
    Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seliciclib in malignancies.
    Aldoss IT; Tashi T; Ganti AK
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
    Coley HM; Shotton CF; Kokkinos MI; Thomas H
    Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
    Gómez-Benito M; Marzo I; Anel A; Naval J
    Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
    Faber AC; Chiles TC
    Cell Cycle; 2007 Dec; 6(23):2982-9. PubMed ID: 18156799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
    Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
    Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
    Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
    Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.